https://doi.org/10.4081/gc.2026.15195
Sarcopenic obesity in older adults: the dual burden of muscle loss and fat gain. Clinical consequences, diagnostic challenges, and integrated management strategies
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 25 June 2026
Published: 2 October 2026
Sarcopenic obesity is an emerging geriatric syndrome defined by the simultaneous presence of reduced skeletal muscle mass and function alongside excess adiposity. As populations age and obesity prevalence rises, this condition has grown in clinical importance, carrying risks of frailty, falls, disability, metabolic syndrome, cardiovascular disease, poor quality of life, and premature mortality that exceed those associated with either condition independently. This narrative review synthesizes current evidence on the epidemiology, pathophysiology, clinical consequences, diagnostic challenges, and management of sarcopenic obesity in older adults. Its development involves a complex interplay of age-related muscle atrophy, adipose tissue dysfunction, chronic low-grade inflammation, insulin resistance, hormonal alterations, mitochondrial impairment, and diminished regenerative capacity, mechanisms that collectively reinforce one another in a self-perpetuating cycle. Diagnosis is hampered by the absence of a universally accepted definition; current frameworks differ in their choice of muscle mass indices, strength thresholds, performance measures, and adiposity cut-offs. Recent international consensus statements have proposed stepwise approaches to improve clinical recognition. Management centers on progressive resistance exercise combined with optimized protein intake and multidisciplinary care. Emerging pharmacological options, notably glucagon-like peptide-1 receptor agonists, offer important metabolic benefits but require careful use in older adults because of the risk of lean mass loss. Early detection, standardized diagnostic frameworks, and integrated lifestyle interventions are essential to mitigate the functional and metabolic burden of sarcopenic obesity.
Downloads
United Nations Department of Economic and Social Affairs. World population ageing 2020 highlights. Available from: https://www.un.org/development/desa/pd/news/world-population-ageing-2020-highlights.
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019;393:2636-46. DOI: https://doi.org/10.1016/S0140-6736(19)31138-9
Beaudart C, Rizzoli R, Bruyère O, et al. Sarcopenia: burden and challenges for public health. Arch Public Health 2014;72:45. DOI: https://doi.org/10.1186/2049-3258-72-45
Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci 2000;904:437-48. DOI: https://doi.org/10.1111/j.1749-6632.2000.tb06498.x
Zamboni M, Mazzali G, Fantin F, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 2008;18:388-95. DOI: https://doi.org/10.1016/j.numecd.2007.10.002
Donini LM, Busetto L, Bauer JM, et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr 2020;39:2368-88. DOI: https://doi.org/10.1016/j.clnu.2019.11.024
Batsis JA, Villareal DT. Sarcopenic obesity in older adults: etiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018;14:513-37. DOI: https://doi.org/10.1038/s41574-018-0062-9
Atkins JL, Whincup PH, Morris RW, et al. Sarcopenic obesity and risk of cardiovascular disease and mortality. J Am Geriatr Soc 2014;62:253-60. DOI: https://doi.org/10.1111/jgs.12652
Prado CM, Wells JCK, Smith SR, et al. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 2012;31:583-601. DOI: https://doi.org/10.1016/j.clnu.2012.06.010
Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004;12:887-8. DOI: https://doi.org/10.1038/oby.2004.107
Barazzoni R, Bischoff SC, Boirie Y, et al. Sarcopenic obesity: time to meet the challenge. Clin Nutr 2018;37:1787-93. DOI: https://doi.org/10.1016/j.clnu.2018.04.018
Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging 2018;22:1148-61. DOI: https://doi.org/10.1007/s12603-018-1139-9
Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obesity 2005;13:1849-63. DOI: https://doi.org/10.1038/oby.2005.228
Yang J, Wang Y, Shi X, et al. Prevalence of sarcopenic obesity among older adults in communities of China: a multicenter, cross-sectional study. Nutr Clin Pract 2024;39:1375-87. DOI: https://doi.org/10.1002/ncp.11214
Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300-7.e2. DOI: https://doi.org/10.1016/j.jamda.2019.12.012
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31. DOI: https://doi.org/10.1093/ageing/afy169
Barazzoni R, Bischoff SC, Busetto L, et al. Sarcopenic obesity: a position statement by ESPEN and EASO. Clin Nutr 2022;41:990-1000. DOI: https://doi.org/10.1016/j.clnu.2021.11.014
Gao Q, Hu K, Yan C, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr 2021;40:4633-41. DOI: https://doi.org/10.1016/j.clnu.2021.06.009
Chen TP, Kao HH, Ogawa W, et al. The Asia-Oceania consensus: definitions and diagnostic criteria for sarcopenic obesity. Obes Res Clin Pract 2025;19:185-92. DOI: https://doi.org/10.1016/j.orcp.2025.05.001
Axelrod CL, Dantas WS, Kirwan JP. Sarcopenic obesity: emerging mechanisms and therapeutic potential. Metabolism 2023;146:155639. DOI: https://doi.org/10.1016/j.metabol.2023.155639
Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care 2004;7:405-10. DOI: https://doi.org/10.1097/01.mco.0000134362.76653.b2
Sakuma K, Yamaguchi A. Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol 2013;2013:204164. DOI: https://doi.org/10.1155/2013/204164
Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci 2020;21:494. DOI: https://doi.org/10.3390/ijms21020494
Jung UJ, Choi MS. Sarcopenic obesity: involvement of oxidative stress and therapeutic strategies. Antioxidants 2023;12:1063. DOI: https://doi.org/10.3390/antiox12051063
Prado CM, Batsis JA, Donini LM, et al. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol 2024;20:261-77. DOI: https://doi.org/10.1038/s41574-023-00943-z
Yang M, Hu X, Xie L, et al. Sarcopenic obesity is associated with frailty among community-dwelling older adults: a cross-sectional study. BMC Geriatr 2022;22:863. DOI: https://doi.org/10.1186/s12877-022-03617-z
Yu C, Meng Z, Wang X, Xiao J. Associations between sarcopenic obesity and risk of falls: a population-based cohort study among middle-aged and older adults using the CHARLS. BMC Public Health 2025;25:3335. DOI: https://doi.org/10.1186/s12889-025-24746-1
Öztürk ZA, Türkbeyler İH, Abiyev A, et al. Health-related quality of life and fall risk associated with age-related body composition changes; sarcopenia, obesity and sarcopenic obesity. Intern Med J 2018;48:973-81. DOI: https://doi.org/10.1111/imj.13935
Zhang Z, Zeng X. Sarcopenic obesity and cardiovascular disease risk and mortality: A systematic review and meta-analysis. Anatol J Cardiol 2025;30:73-82. DOI: https://doi.org/10.14744/AnatolJCardiol.2025.5635
Manrique-Espinoza B, Salinas-Rodríguez A, Rosas-Carrasco O, et al. Sarcopenia is associated with physical and mental components of health-related quality of life in older adults. J Am Med Dir Assoc 2017;18:636.e1-5. DOI: https://doi.org/10.1016/j.jamda.2017.04.005
Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia and sarcopenic obesity and mortality among older adults. JAMA Netw Open 2024;7:e243604. DOI: https://doi.org/10.1001/jamanetworkopen.2024.3604
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002. DOI: https://doi.org/10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. DOI: https://doi.org/10.1056/NEJMoa2206038
CRediT authorship contribution
Harishchandra Chaudhari, Yashodeep Gaikwad: conceptualization, methodology, writing–original draft. Gaurav Chaudhary: methodology, writing–review and editing. Anu Gaikwad: conceptualization, writing–review and editing.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.